Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors

NCT04853017 is registered in ClinicalTrials.gov with Elicio Therapeutics as lead sponsor.

NCT NCT04853017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04853017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Lead sponsor
Elicio Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
October 4, 2021
Completion date
September 24, 2024
Enrollment
25 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, cholangiocarcinoma, colorectal cancer, gallbladder carcinoma, kras g12d, kras g12r, minimal residual disease, non-small cell lung cancer, nras g12d, nras g12r, ovarian cancer, pancreatic ductal adenocarcinoma